Regulatory T cells control toxicity in a humanized model of IL-2 therapy

High dose IL-2 is a viable treatment option for cancer immune therapy, but the underlying mechanism for the accompanying undesirable morbidity is unclear. Here the authors show, using human immune system mouse models, that regulatory T cells and their functions on effector T cells are essential modu...

Full description

Bibliographic Details
Main Authors:	Yan Li, Helene Strick-Marchand, Ai Ing Lim, Jiazi Ren, Guillemette Masse-Ranson, Dan Li, Gregory Jouvion, Lars Rogge, Sophie Lucas, Bin Li, James P. Di Santo
Format:	Article
Language:	English
Published:	Nature Publishing Group 2017-11-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-017-01570-9

id	doaj-80f477ac6ea64fb69ea9a165783a2311
record_format	Article
spelling	doaj-80f477ac6ea64fb69ea9a165783a23112021-05-11T07:02:29ZengNature Publishing GroupNature Communications2041-17232017-11-018111210.1038/s41467-017-01570-9Regulatory T cells control toxicity in a humanized model of IL-2 therapyYan Li0Helene Strick-Marchand1Ai Ing Lim2Jiazi Ren3Guillemette Masse-Ranson4Dan Li5Gregory Jouvion6Lars Rogge7Sophie Lucas8Bin Li9James P. Di Santo10Institut Pasteur, Innate Immunity Unit, Immunology DepartmentInstitut Pasteur, Innate Immunity Unit, Immunology DepartmentInstitut Pasteur, Innate Immunity Unit, Immunology DepartmentKey Laboratory of Molecular Virology and Immunology, CAS Center for Excellence in Molecular Cell Science, Unit of Molecular Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of SciencesInstitut Pasteur, Innate Immunity Unit, Immunology DepartmentKey Laboratory of Molecular Virology and Immunology, CAS Center for Excellence in Molecular Cell Science, Unit of Molecular Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of SciencesInstitut Pasteur, Human Histopathology and Animal Models UnitInstitut Pasteur, Immunoregulation Unit, Immunology Departmentde Duve Institute, Université Catholique de Louvain, and WELBIOKey Laboratory of Molecular Virology and Immunology, CAS Center for Excellence in Molecular Cell Science, Unit of Molecular Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of SciencesInstitut Pasteur, Innate Immunity Unit, Immunology DepartmentHigh dose IL-2 is a viable treatment option for cancer immune therapy, but the underlying mechanism for the accompanying undesirable morbidity is unclear. Here the authors show, using human immune system mouse models, that regulatory T cells and their functions on effector T cells are essential modulators of the related pathogenesis.https://doi.org/10.1038/s41467-017-01570-9
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Yan Li Helene Strick-Marchand Ai Ing Lim Jiazi Ren Guillemette Masse-Ranson Dan Li Gregory Jouvion Lars Rogge Sophie Lucas Bin Li James P. Di Santo
spellingShingle	Yan Li Helene Strick-Marchand Ai Ing Lim Jiazi Ren Guillemette Masse-Ranson Dan Li Gregory Jouvion Lars Rogge Sophie Lucas Bin Li James P. Di Santo Regulatory T cells control toxicity in a humanized model of IL-2 therapy Nature Communications
author_facet	Yan Li Helene Strick-Marchand Ai Ing Lim Jiazi Ren Guillemette Masse-Ranson Dan Li Gregory Jouvion Lars Rogge Sophie Lucas Bin Li James P. Di Santo
author_sort	Yan Li
title	Regulatory T cells control toxicity in a humanized model of IL-2 therapy
title_short	Regulatory T cells control toxicity in a humanized model of IL-2 therapy
title_full	Regulatory T cells control toxicity in a humanized model of IL-2 therapy
title_fullStr	Regulatory T cells control toxicity in a humanized model of IL-2 therapy
title_full_unstemmed	Regulatory T cells control toxicity in a humanized model of IL-2 therapy
title_sort	regulatory t cells control toxicity in a humanized model of il-2 therapy
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2017-11-01
description	High dose IL-2 is a viable treatment option for cancer immune therapy, but the underlying mechanism for the accompanying undesirable morbidity is unclear. Here the authors show, using human immune system mouse models, that regulatory T cells and their functions on effector T cells are essential modulators of the related pathogenesis.
url	https://doi.org/10.1038/s41467-017-01570-9
work_keys_str_mv	AT yanli regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT helenestrickmarchand regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT aiinglim regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT jiaziren regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT guillemettemasseranson regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT danli regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT gregoryjouvion regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT larsrogge regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT sophielucas regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT binli regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy AT jamespdisanto regulatorytcellscontroltoxicityinahumanizedmodelofil2therapy
_version_	1721452930936078336

Regulatory T cells control toxicity in a humanized model of IL-2 therapy

Similar Items